Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
July 21, 2016
Revance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016
July 14, 2016
Revance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines
July 5, 2016
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
June 13, 2016
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
June 2, 2016
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
May 31, 2016
Revance to Participate in Upcoming Investor Conferences
May 9, 2016
Revance Releases First Quarter 2016 Results
April 25, 2016
Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016
April 4, 2016
Abhay Joshi, PhD, MBA, Chief Operating Officer of Revance, Honored by the American Institute for Medical and Biological Engineering (AIMBE)
March 14, 2016
Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development
Displaying 221 - 230 of 298